Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Bionet TherapeuticsROCO:7808 12 Altman Z2-Score is 23.29 as of Jul. 15, 2026, which is 13% below its 10-year median of 26.91. GuruFocus rates ROCO:7808 with a GF Score™ of 12/100. The stock has 2 warning signs investors should review. Among 1,392 Biotechnology companies, Bionet Therapeutics ranks better than 94.54% on this metric.
Altman Z2-Score, also known as Z"-Score, is used to predict the likelihood that a non-manufacturing company (excluding property/financial company) will face bankruptcy within a two-year period.
Good Sign:
Bionet Therapeutics has a Altman Z2-Score of 23.29, indicating it is in Safe Zones. This implies the Altman Z2-Score is strong.
The zones of discrimination were as such:
When Altman Z2-Score <= 1.1, it is in Distress Zones.
When Altman Z2-Score >= 2.6, it is in Safe Zones.
When Altman Z2-Score is between 1.1 and 2.6, it is in Grey Zones.
The historical rank and industry rank for Bionet Therapeutics's Altman Z2-Score or its related term are showing as below:
ROCO:7808'
s Altman Z2-Score Range Over the Past 10 Years
Min: 13.98 Med: 26.91 Max: 51.39
Current: 23.29
During the past 4 years, Bionet Therapeutics's highest Altman Z2-Score was 51.39. The lowest was 13.98. And the median was 26.91.
The original Z-Score model was based on publicly traded manufacturing companies while the Z2-Score, also known as Z"-score can be used for any type of company excluding property/financial companies. Both Z-Score and Z2-Score describes the financial health of a company, and its likelihood of financial distress.
X1: The Working Capital/Total Assets (WC/TA) ratio is a measure of the net liquid assets of the firm relative to the total capitalization. Working capital is defined as the difference between current assets and current liabilities. Ordinarily, a firm experiencing consistent operating losses will have shrinking current assets in relation to total assets. Altman found this one proved to be the most valuable liquidity ratio comparing with the current ratio and the quick ratio. This is however the least significant of the five factors.
X2: Retained Earnings/Total Assets: the RE/TA ratio measures the leverage of a firm. Retained earnings is the account which reports the total amount of reinvested earnings and/or losses of a firm over its entire life. Those firms with high RE, relative to TA, have financed their assets through retention of profits and have not utilized as much debt.
X3, Earnings Before Interest and Taxes/Total Assets (EBIT/TA): This ratio is a measure of the true productivity of the firm's assets, independent of any tax or leverage factors. Since a firm's ultimate existence is based on the earning power of its assets, this ratio appears to be particularly appropriate for studies dealing with corporate failure. This ratio continually outperforms other profitability measures, including cash flow.
Altman Z2-Score does not apply to financial companies.
Bionet Therapeutics Altman Z2-Score Related Terms
Bionet Therapeutics Altman Z2-Score Historical Data
* Premium members only.
The historical data trend for Bionet Therapeutics's Altman Z2-Score can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:7808 vs VRTX, REGN, ALNY: Altman Z2-Score Comparison
For the Biotechnology subindustry, Bionet Therapeutics's Altman Z2-Score, along with its competitors' market caps and Altman Z2-Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bionet Therapeutics Altman Z2-Score vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Bionet Therapeutics's Altman Z2-Score distribution charts can be found below:
* The bar in red indicates where Bionet Therapeutics's Altman Z2-Score falls into.
Altman Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.
Z2-Score, also known as Z"-Score is the Z-Score for non-manufacturing companies excluding property/financial companies.
Bionet Therapeutics's Altman Z2-Score for today is calculated with this formula:
Z
=
6.56
*
X1
+
3.26
*
X2
+
6.72
*
X3
+
1.05
*
X4_2
=
6.56
*
0.8418
+
3.26
*
-0.1801
+
6.72
*
-0.0759
+
1.05
*
17.9664
=
23.29
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency. GuruFocus does not calculate Altman Z2-Score when X4_2 value is 0.
Bionet Therapeutics (ROCO:7808) has a Altman Z2-Score of 23.29 as of Jul. 15, 2026. Z2-Score is the Z-Score for non-manufacturing companies excluding property/financial companies, which measures a company's bankruptcy risk. View historical data on Bionet Therapeutics and its competitors. This is 13% below median its historical median of 26.91. Over the past decade, Bionet Therapeutics' Altman Z2-Score has ranged from 13.98 to 51.39. According to the industry distribution chart, Bionet Therapeutics ranks #76 out of 1392 companies in the Biotechnology industry, placing it in the top 5.5%.
Is Bionet Therapeutics' Altman Z2-Score too high?
Bionet Therapeutics' current Altman Z2-Score of 23.29 is 13% below median its 10-year median of 26.91. Over the past 10 years, this metric has ranged from a low of 13.98 to a high of 51.39. Based on the distribution chart, Bionet Therapeutics ranks #76 out of 1392 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Bionet Therapeutics has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Bionet Therapeutics' Altman Z2-Score compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Bionet Therapeutics ranks #76 out of 1392 companies for Altman Z2-Score. This places Bionet Therapeutics in the top 6% of its industry — outperforming the majority of peers. Historically, Bionet Therapeutics' own Altman Z2-Score has ranged from 13.98 to 51.39 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Altman Z2-Score for a Biotechnology company?
A good Altman Z2-Score depends on the Biotechnology industry context. However, Altman Z2-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Altman Z2-Score mean?
A high Altman Z2-Score can signal that a stock is expensive relative to its fundamentals. Z2-Score is the Z-Score for non-manufacturing companies excluding property/financial companies, which measures a company's bankruptcy risk. View historical data on Bionet Therapeutics and its competitors. Bionet Therapeutics's current Altman Z2-Score is 23.29, which is 13% below median its own 10-year median of 26.91. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bionet Therapeutics stock overvalued right now?
Bionet Therapeutics (ROCO:7808) has a current Altman Z2-Score of 23.29. The current Altman Z2-Score is 23.29, which is 13% below median its 10-year median of 26.91. Bionet Therapeutics' overall GF Score™ is 12/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Altman Z2-Score calculated?
Altman Z2-Score is calculated from a company's financial statements. For Bionet Therapeutics (ROCO:7808), the current Altman Z2-Score is 23.29 as of Jul. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Bionet Therapeutics Corp is a patient-focused on regenerative medicinal products, R&D, exosomes, and gene/cell therapy biopharmaceutical company. The group develops, manufactures, and provides regenerative medicine preparations and cellular therapies to meet the evolving health needs of people at different stages of life. It focused on treatments that improve patient outcomes. It provides Cell Therapy Products and CRDMO Services.
12GF Score
Get the complete analysis for ROCO:7808
Altman Z2-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:7808 has been successfully added to your 
